Figure 1

(a) Probabilities of OS based on day 28 response in patients with steroid-refractory aGVHD after anti-CD25 mAb therapy. (b) Cumulative incidence of NRM based on day 28 response in patients with steroid-refractory aGVHD after anti-CD25 mAb therapy.